Angela Wasunna is Vice President, Emerging Markets Policy at Pfizer. In her role, she is responsible for leading the development and implementation of a coordinated approach to advance business-focused policy issues related to drug pricing, intellectual property, health systems, healthcare financing and regulatory reform in Emerging Markets. Previously Angela was Assistant General Counsel, Intellectual Property Policy in Pfizer’s Legal Division. Angela received her law degree from the University of Nairobi Kenya, and advanced law degrees from McGill University, Canada and Harvard Law School. She is admitted to practice law in the State of New York and is an Advocate of the High Court of Kenya. Before moving to Pfizer, Angela was Associate for International Programs at the Hastings Center for Bioethics, New York. At the Hastings Center, she managed projects on intellectual property rights, market mechanisms in health systems, and public health policy. Angela has also served as consultant to several agencies including the World Health Organization, the Institute of Medicine (IOM), the Centers for Disease Control (CDC), the World Health Organization, the Bill and Melinda Gates Foundation, the World Bank and the Department for International Development, UK (DFID). Angela has published several peer-reviewed articles in academic journals, and lectured internationally. She is co-author of the book: Medicine and the Market: Equity v Choice, Johns Hopkins University Press, 2006.